TY - JOUR
AB - Breast cancer is the second most common cancer in the world based on incidence, reaching more than 2 million new cases in 2018, while continuing to increase. Invasive ductal carcinoma is the most common type of this cancer, making up approximately 70‑80% of all breast cancer diagnoses. In particular, the type of breast cancer overexpressing human epidermal growth factor receptor 2 (HER2) has potential of strong proliferation, migration and invasion and early treatment is necessary. The authors identified and studied a single patient displaying complete therapeutic resistance to monoclonal anti‑HER2 antibody therapy, chemotherapy and radiotherapy. A patient who exhibited resistance to postoperative adjuvant therapy after mastectomy was selected from HER2‑positive breast cancer, and this patient had the grade of T4bN2aM0, Stage IIIB. The patient samples, blood serum and cancer tissue, were analyzed by metabolome and immunostaining technique, respectively. The characteristics of peripheral blood serum and solid tumor were investigated, aiming to find new serum biomarker(s) using the metabolomics technique. A correlation between the appearance of HER2‑positive cancer tissue and serum concentration of the sphingomyelin family was found. In addition, HER2‑positive tumor tissue in both the primary and recurrent cancer express the sphingomyelinase. These results suggest that sphingomyelins from this cancer tissue leads to therapy resistance, induction of invasion and strong proliferation.
AD - Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
Department of Glycotechnology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
Department of Radiology, Mutsu General Hospital, Mutsu, Aomori 035‑0071, Japan
Department of Bioscience and Laboratory Medicine, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori 036‑8564, Japan
Centre for Radiation Protection Research, Department of Molecular Biosciences, The Wenner‑Gren Institute, Stockholm University, 114 18 Stockholm, Sweden
AU - Monzen,Satoru
AU - Tatara,Yota
AU - Mariya,Yasushi
AU - Chiba,Mitsuru
AU - Wojcik,Andrzej
AU - Lundholm,Lovisa
DA - 2020/12/01
DO - 10.3892/mco.2020.2140
IS - 6
JO - Mol Clin Oncol
KW - HER2-positive breast cancer
postoperative adjuvant therapy
resistant
metabolomics analysis
sphingomyeline
PY - 2020
SN - 2049-9450
2049-9469
SP - 70
ST - HER2‑positive breast cancer that resists therapeutic drugs and ionizing radiation releases sphingomyelin‑based molecules to circulating blood serum
T2 - Molecular and Clinical Oncology
TI - HER2‑positive breast cancer that resists therapeutic drugs and ionizing radiation releases sphingomyelin‑based molecules to circulating blood serum
UR - https://doi.org/10.3892/mco.2020.2140
VL - 13
ER -